Search Result

Results for "

migraines

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (58) Adrenergic Receptor (7) AMPK (1) Apoptosis (8) Aquaporin (1) Autophagy (14) Biochemical Assay Reagents (2) Calcium Channel (1) Cannabinoid Receptor (1) Caspase (1) CGRP Receptor (30) Cytochrome P450 (1) Dengue Virus (1) Dopamine Receptor (2) Drug Derivative (2) Drug Intermediate (1) Endogenous Metabolite (27) Epigenetic Reader Domain (1) ERK (2) Flavivirus (1) GABA Receptor (2) HDAC (14) Heme Oxygenase (HO) (1) Histamine Receptor (2) HIV (14) iGluR (2) Isotope-Labeled Compounds (21) Keap1-Nrf2 (1) mGluR (3) Mitophagy (14) NADPH Oxidase (2) NO Synthase (2) Notch (14) Organoid (6) Potassium Channel (2) Prostaglandin Receptor (2) Reference Standards (13) Sodium Channel (1) TRP Channel (5)
By Research Areas:	Cancer (20) Cardiovascular Disease (24) Infection (9) Inflammation/Immunology (29) Metabolic Disease (16) Neurological Disease (119)

By Targets:

5-HT Receptor (58)

Adrenergic Receptor (7)

AMPK (1)

Apoptosis (8)

Aquaporin (1)

Autophagy (14)

Biochemical Assay Reagents (2)

Calcium Channel (1)

Cannabinoid Receptor (1)

Caspase (1)

CGRP Receptor (30)

Cytochrome P450 (1)

Dengue Virus (1)

Dopamine Receptor (2)

Drug Derivative (2)

Drug Intermediate (1)

Endogenous Metabolite (27)

Epigenetic Reader Domain (1)

ERK (2)

Flavivirus (1)

GABA Receptor (2)

HDAC (14)

Heme Oxygenase (HO) (1)

Histamine Receptor (2)

HIV (14)

iGluR (2)

Isotope-Labeled Compounds (21)

Keap1-Nrf2 (1)

mGluR (3)

Mitophagy (14)

NADPH Oxidase (2)

NO Synthase (2)

Notch (14)

Organoid (6)

Potassium Channel (2)

Prostaglandin Receptor (2)

Reference Standards (13)

Sodium Channel (1)

TRP Channel (5)

By Research Areas:

Cancer (20)

Cardiovascular Disease (24)

Infection (9)

Inflammation/Immunology (29)

Metabolic Disease (16)

Neurological Disease (119)

143

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585

Valproic acid Maximum Cited Publications 65 Publications Verification VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium Maximum Cited Publications 65 Publications Verification Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-P0203

α-CGRP (mouse, rat) 5+ Cited Publications CGRP (83-119), mouse, rat	CGRP Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
α-CGRP (mouse, rat), a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .

HY-15498

Rimegepant 5+ Cited Publications BMS-927711; BHV-3000	CGRP Receptor	Neurological Disease
Rimegepant (BMS-927711) is an orally bioavailable and blood-brain barrier permeable antagonist of CGRP and AMY1 receptors, with a pIC₅₀ of 8.01 and a K_i of 0.027 nM for human CGRP receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at CGRP and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to *migraine* .

HY-B0670A

Dihydroergotamine mesylate 5 Publications Verification	5-HT Receptor	Infection Neurological Disease Metabolic Disease Cancer
Dihydroergotamine mesylate is a BBB-permeable ergot alkaloid that can be used for the research of migraines .

HY-109022

Atogepant MK-8031; AGN-241689	CGRP Receptor	Neurological Disease
Atogepant (MK-8031) is an orally active and selective calcitonin gene-related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine .

HY-B0121B

Sumatriptan 5+ Cited Publications GR 43175 free base	5-HT Receptor	Neurological Disease
Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-12366

Ubrogepant MK-1602	CGRP Receptor	Cardiovascular Disease Neurological Disease
Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .

HY-10301

MK-3207 5 Publications Verification	CGRP Receptor	Neurological Disease
MK-3207 is an orally active, highly selective and species-specific CGRP receptor antagonist (for human CGRP receptor: IC₅₀=0.12 nM; K_i=0.024 nM). MK-3207 can be used for migraine studies .

HY-12713

Lisuride	Dopamine Receptor	Neurological Disease
Lisuride is an orally active dopamine D2 receptors agonist. Lisuride, as an ergot derivative, can be used for the research of Parkinson's disease, migraine, and high prolactin levels .

HY-P99021

Galcanezumab 1 Publications Verification LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

HY-134992

Vazegepant Zavegepant; BHV-3500	CGRP Receptor	Neurological Disease
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist. Vazegepant can be used in the study of migraine .

HY-P9938

Erenumab 1 Publications Verification AMG-334	CGRP Receptor	Neurological Disease
Erenumab (AMG-334) is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine .

HY-B0121

Sumatriptan succinate 5+ Cited Publications GR 43175 succinate	5-HT Receptor	Neurological Disease
Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research .

HY-B0229

Zolmitriptan BW-311C90; 311C90	5-HT Receptor Endogenous Metabolite	Neurological Disease
Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist that can cross the blood-brain barrier, with K_is of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .

HY-N0745

Senkyunolide I	Caspase ERK Keap1-Nrf2 Heme Oxygenase (HO) Apoptosis	Neurological Disease Inflammation/Immunology
Senkyunolide I is an orally active, blood-brain barrier-permeable metabolite of Z-ligustilide (HY-N0401A) . Senkyunolide I is isolated from Ligusticum chuanxiong. Senkyunolide I upregulates p-Erk1/2 and Nrf2/HO-1, and inhibits Caspase 3. Senkyunolide I alleviates Apoptosis. Senkyunolide I increases the pain threshold in mice and reduces acetic acid-induced writhing responses in mice. Senkyunolide I improves neurological deficits, reduces infarct volume and alleviates cerebral edema in rats with focal cerebral ischemia-reperfusion injury. Senkyunolide I protects renal function and structural integrity in a mouse model of renal ischemia-reperfusion injury. Senkyunolide I is applicable to research related to focal cerebral ischemia-reperfusion injury, migraine, and renal ischemia-reperfusion injury .

HY-15498A

Rimegepant sulfate hydrate 5+ Cited Publications BMS-927711 sulfate hydrate; BHV-3000 sulfate hydrate	CGRP Receptor	Neurological Disease
Rimegepant (BMS-927711) sulfate hydrate is a potent, orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a K_i of 0.027 nM and an IC₅₀ of 0.14 nM for hCGRP receptor. Rimegepant sulfate hydrate can be used for migraine research .

HY-P99017

Eptinezumab ALD-403	CGRP Receptor	Neurological Disease
Eptinezumab (ALD-403) is a human monoclonal antibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the CGRP ligand and blocks its binding to endogenous CGRP receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .

HY-P99019

Fremanezumab 2 Publications Verification TEV-48125; LBR-101; PF-04427429; RN-307	CGRP Receptor	Neurological Disease Inflammation/Immunology
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC₅₀ values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC₅₀ value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .

HY-B0383

Almotriptan malate PNU180638	5-HT Receptor	Neurological Disease
Almotriptan malate (PNU180638) is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan malate shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan malate induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan malate can be used in research related to migraine .

HY-B1804

Tricaprilin Trioctanoin; Glyceryl trioctanoate	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-P0203A

α-CGRP (mouse, rat) TFA 5+ Cited Publications CGRP (83-119), mouse, rat TFA	CGRP Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
α-CGRP (mouse, rat) TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .

HY-17494

Timolol (S)-L-714,465; MK 950 free base	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .

HY-B1658A

Frovatriptan succinate hydrate (R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; VML 251 succinate hydrate	5-HT Receptor	Neurological Disease
Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT_1B (pK₅₀ of 8.2) and 5-HT_1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT_1B and 5-HT_1D over 5-HT_1A, 5-HT_1F, and 5-HT₇ and >1000-fold selectivity over other 5-HT, dopamine, histamine H₁, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .

HY-13788

LY 344864 2 Publications Verification	5-HT Receptor Adrenergic Receptor	Neurological Disease
LY 344864 is a selective, orally active 5-HT_1F receptor agonist with a K_i of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent .

HY-10585R

Valproic acid (Standard) 45+ Cited Publications VPA (Standard); 2-Propylpentanoic acid (Standard); Dipropylacetic acid (Standard)	Reference Standards Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Dipropylacetic Acid) (Standard) is an analytical standard for valproic acid. This product is intended for research and analytical applications. Valproic acid is an orally active HDAC inhibitor (IC₅₀=0.5-2 mM), inhibits the activity of HDAC1 (IC₅₀=400 μM), and induces the degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits the proliferation of small cell lung cancer (SCLC) cells. Valproic acid is used in the study of epilepsy, bipolar disorder, metabolic diseases, HIV infection, and migraine .

HY-100129

JNJ-17203212 1 Publications Verification	TRP Channel	Neurological Disease
JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine .

HY-B0383A

Almotriptan PNU180638 free base	5-HT Receptor	Neurological Disease
Almotriptan (PNU180638 free base) is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan can be used in research related to migraine .

HY-P0203B

β-CGRP (mouse) Calcitonin gene-related peptide 2 (mouse); CGRP II (mouse)	CGRP Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
β-CGRP (mouse) is a calcitonin gene-related peptide that induces vasodilation. β-CGRP (mouse) can be utilized in cardiovascular, pro-inflammatory, migraine and metabolic research .

HY-B1170

Cyclandelate 3,5,5-Trimethylcyclohexyl mandelate	Calcium Channel	Cardiovascular Disease
Cyclandelate is a vasodilator that can be used in the study of claudication, arteriosclerosis, Raynaud's disease, nocturnal leg cramps, and migraines.

HY-78509

Dibenzosuberone	Biochemical Assay Reagents Drug Intermediate	Neurological Disease
Dibenzosuberone belongs to the family of tricyclic antidepressant drugs, commonly referred to as Tricyclic antidepressants (TCAs), and is widely used in research on migraine, tension headaches, anxiety disorders, and schizophrenia. Dibenzosuberone is also a key intermediate in the synthesis of various active pharmaceutical ingredients (APIs), such as Amitriptyline (HY-B0527), Nortriptyline (HY-118620), Noxiptiline or Cyproheptadine (HY-B1622) .

HY-172182

ONO-2920632 VU6011887	Potassium Channel	Neurological Disease
ONO-2920632 is an orally active and central nervous system (CNS)-penetrant TREK activator, with EC₅₀ values of 0.3 µM and 2.8 μM for TREK-1 and TREK-2, respectively. ONO-2920632 exhibits selectivity for other K2P channels (>91-fold selective versus TASK1, TASK2, TASK3, TRAAK, and TWIK2; 31-fold selective versus TRESK). ONO-2920632 possesses analgesic effects and can be used in research on pain, migraine, and neurological disorders.

HY-B1804S

Tricaprilin-13C3 Trioctanoin-¹³C₃; Glyceryl trioctanoate-¹³C₃	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Tricaprilin- ¹³C₃ (Trioctanoin- ¹³C₃) is a ¹³C-labeled Tricaprilin (HY-B1804) . Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-117694

MK-8825	CGRP Receptor	Neurological Disease Inflammation/Immunology
MK-8825 is an orally active, selective CGRP receptor antagonist with a K_i value of 47 pM for human CGRP receptors and 17 nM for rat CGRP receptors. MK-8825 blocks CGRP-stimulated cAMP responses and exhibits competitive-like antagonism. MK-8825 can be used in the research of migraine and temporomandibular joint disorders .

HY-135809

A2764 dihydrochloride	Potassium Channel	Neurological Disease
A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K ⁺ channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC₅₀=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-120837

PZ-II-029	GABA Receptor	Neurological Disease
PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to α6β3γ2. PZ-II-029 shows anti-migraine effects .

HY-103574

Raseglurant hydrochloride ADX-10059 hydrochloride	mGluR	Neurological Disease
Raseglurant hydrochloride is a negative allosteric modulator of mGluR5. Raseglurant hydrochloride can be used in study migraine .

HY-101698

Alniditan Alnitidan	5-HT Receptor	Neurological Disease Inflammation/Immunology
Alniditan (Alnitidan) is a potent 5-HT_1B and 5-HT_1D receptors agonist, with IC₅₀s of 1.7 nM and 1.3 nM for h5-HT_1B and h5-HT_1D receptors in HEK293 cells, respectively. Alniditan has migraine-preventive effects .

HY-120294

Chrysin 6-C-glucoside 8-C-arabinoside	CGRP Receptor TRP Channel	Neurological Disease
Chrysin 6-C-glucoside 8-C-arabinoside can inhibit the CGRP releasing and the activation of TRPV1 channel. Chrysin 6-C-glucoside 8-C-arabinoside can be used for anti-migraine research .

HY-124277

ADM 12	TRP Channel	Neurological Disease
ADM 12 is a highly selective transient receptor potential ankyrin 1 (TRPA1) channel antagonist. ADM 12 blocks nitroglycerin (NTG)-induced trigeminal hyperalgesia in animal models, reducing expression of pain-related genes (c-Fos, TRPA1) and neuropeptides (CGRP, SP). ADM_12 is promising for research of migraine and neuropathic pain .

HY-A0039

Eletriptan UK-116044	5-HT Receptor	Neurological Disease Inflammation/Immunology
Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT_1B and 5-HT_1D receptor agonist, with pK_i values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .

HY-14866

Raseglurant ADX-10059	mGluR	Neurological Disease
Raseglurant (ADX-10059) is a mGlu5 receptor negative allosteric modulator. Raseglurant is effective against migraine. Raseglurant reduces the Haloperidol (HY-14538)-induced catalepsy in mice .

HY-12367

BMS-846372	CGRP Receptor	Cardiovascular Disease
BMS-846372 (Compound 5) is an orally active CGRP antagonist (K_i = 0.07 nM). BMS-846372 may be used in migraine research .

HY-B0670

Dihydroergotamine DFN-19	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease Neurological Disease
Dihydroergotamine (DFN-19) is a BBB-permeable and semisynthetic, hydrogenated ergot alkaloid. Dihydroergotamine can cause vasoconstriction by stimulating alpha-adrenergic and 5-HT_2A receptors. Dihydroergotamine can be used in the research of migraine .

HY-109022A

(3R,5R,6S)-Atogepant (3R,5R,6S)-MK-8031; (3R,5R,6S)-AGN-241689	CGRP Receptor	Neurological Disease
(3R,5R,6S)-Atogepant ((3R,5R,6S)-MK-8031) is the enantiomer of Atogepant (HY-109022). Atogepant is a calcitonin gene-related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine.

HY-114678

LY302148	5-HT Receptor	Neurological Disease
LY302148 is a receptor ligand for 5-HT_1F. Compared to the E_max of 5-HT, LY302148 behaves as a partial agonist for the 5-HT_1F receptor. In the [ ³⁵S]GTPγS binding assay targeting human 5-HT_1F receptors, LY302148 exhibits good potency with an EC₅₀ value of 5.23 nM. LY302148 can be used in the research of migraine .

HY-19238

BMS-181885	5-HT Receptor	Neurological Disease
BMS-181885 is a selective 5-HT₁ receptor agonist and a ligand for 5-HT_1B/_1D receptors. BMS-181885 exhibits anti-migraine activity. BMS-181885 can be used in the research of neurological diseases such as migraine .

HY-176297

Tezampanel etibutil	AMPK iGluR	Neurological Disease
Tezampanel etibutil is an orally active AMPA/GluR antagonist. Tezampanel etibutil can be used in the research of pain, migraine, and neurological disorders .

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Fluorescent Dye

Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P0203

α-CGRP (mouse, rat) 5+ Cited Publications CGRP (83-119), mouse, rat	CGRP Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
α-CGRP (mouse, rat), a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .

HY-P0203A

α-CGRP (mouse, rat) TFA 5+ Cited Publications CGRP (83-119), mouse, rat TFA	CGRP Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
α-CGRP (mouse, rat) TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .

HY-P0203B

β-CGRP (mouse) Calcitonin gene-related peptide 2 (mouse); CGRP II (mouse)	CGRP Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
β-CGRP (mouse) is a calcitonin gene-related peptide that induces vasodilation. β-CGRP (mouse) can be utilized in cardiovascular, pro-inflammatory, migraine and metabolic research .

HY-P2428

RI-61	Endogenous Metabolite	Neurological Disease
RI-61 is a compound that has activity in suppressing migraine, cluster headache, new daily persistent headache and cyclical vomiting syndrome. RI-61 has shown significant efficacy in relieving the symptoms of these disorders. RI-61 helps relieve pain and other related symptoms by modulating the action of neurotransmitters .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99021

Galcanezumab 1 Publications Verification LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

HY-P9938

Erenumab 1 Publications Verification AMG-334	CGRP Receptor	Neurological Disease
Erenumab (AMG-334) is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine .

HY-P99017

Eptinezumab ALD-403	CGRP Receptor	Neurological Disease
Eptinezumab (ALD-403) is a human monoclonal antibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the CGRP ligand and blocks its binding to endogenous CGRP receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .

HY-P99019

Fremanezumab 2 Publications Verification TEV-48125; LBR-101; PF-04427429; RN-307	CGRP Receptor	Neurological Disease Inflammation/Immunology
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC₅₀ values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC₅₀ value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10585

Valproic acid Maximum Cited Publications 65 Publications Verification VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium Maximum Cited Publications 65 Publications Verification Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-B1716

L-5-Hydroxytryptophan 3 Publications Verification L-5-HTP; Oxitriptan	Monophenols other families Phenols Amino acids Plants Endogenous metabolite	Endogenous Metabolite
L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-B0229

Zolmitriptan BW-311C90; 311C90	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Indole Alkaloids Source Classification	5-HT Receptor Endogenous Metabolite
Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist that can cross the blood-brain barrier, with K_is of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .

HY-N0745

Senkyunolide I	Structural Classification Natural Products Classification of Application Fields Dicerothamnus rhinocerotis Umbelliferae Plants Inflammation/Immunology Disease Research Fields Source Classification	Caspase ERK Keap1-Nrf2 Heme Oxygenase (HO) Apoptosis
Senkyunolide I is an orally active, blood-brain barrier-permeable metabolite of Z-ligustilide (HY-N0401A) . Senkyunolide I is isolated from Ligusticum chuanxiong. Senkyunolide I upregulates p-Erk1/2 and Nrf2/HO-1, and inhibits Caspase 3. Senkyunolide I alleviates Apoptosis. Senkyunolide I increases the pain threshold in mice and reduces acetic acid-induced writhing responses in mice. Senkyunolide I improves neurological deficits, reduces infarct volume and alleviates cerebral edema in rats with focal cerebral ischemia-reperfusion injury. Senkyunolide I protects renal function and structural integrity in a mouse model of renal ischemia-reperfusion injury. Senkyunolide I is applicable to research related to focal cerebral ischemia-reperfusion injury, migraine, and renal ischemia-reperfusion injury .

HY-B1804

Tricaprilin Trioctanoin; Glyceryl trioctanoate	Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-B1716R

L-5-Hydroxytryptophan (Standard) 3 Publications Verification L-5-HTP (Standard); Oxitriptan (Standard)	Structural Classification Alkaloids Monophenols other families Ketones, Aldehydes, Acids Phenols Amino acids Plants Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
L-5-Hydroxytryptophan (Standard) is the analytical standard of L-5-Hydroxytryptophan. This product is intended for research and analytical applications. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-120294

Chrysin 6-C-glucoside 8-C-arabinoside	Flavonoids Rheum palmatum L. Flavones Polygonaceae Plants Source Classification	CGRP Receptor TRP Channel
Chrysin 6-C-glucoside 8-C-arabinoside can inhibit the CGRP releasing and the activation of TRPV1 channel. Chrysin 6-C-glucoside 8-C-arabinoside can be used for anti-migraine research .

Cat. No.	Product Name	Chemical Structure

HY-10585S

Valproic acid-d4

1 Publications Verification

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-B1716S

L-5-Hydroxytryptophan-d3

L-5-Hydroxytryptophan-d₃ is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-B1804S

Tricaprilin-13C3

Tricaprilin- ¹³C₃ (Trioctanoin- ¹³C₃) is a ¹³C-labeled Tricaprilin (HY-B1804) . Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-B1716S2

L-5-Hydroxytryptophan-d4

L-5-Hydroxytryptophan-d₄ (L-5-HTP-d₄; Oxitriptan-d₄) is a deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-A0039S1

Eletriptan-d5
Eletriptan-d₅ is the deuterium labeled Eletriptan . Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-B0229S

Zolmitriptan-d6
Zolmitriptan-d₆ is deuterium labeled Zolmitriptan. Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with K_is of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .

HY-B0197AS

Naratriptan-d3 hydrochloride

Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan hydrochloride (HY-B0197A). Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-B0121BS2

Sumatriptan-d5
Sumatriptan-d₅ is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-B1804S1

Tricaprilin-d50

Tricaprilin-d₅₀ (Trioctanoin-d₅₀) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-B1804S2

Tricaprilin-d15

Tricaprilin-d₁₅ (Trioctanoin-d₁₅) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .

HY-134992S

(Rac)-Vazegepant-13C,d3
(Rac)-Vazegepant- ¹³C,d₃ is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine .

HY-B1658S

Frovatriptan-d3 hydrochloride
Frovatriptan-d₃ (hydrochloride) is the deuterium labeled Frovatriptan . Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .

HY-17494S1

Timolol-d9 maleate

Timolol-d₉ (maleate) is deuterium labeled Timolol. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .

HY-A0039S2

Eletriptan-d5 hydrochloride

Eletriptan-d₅ (hydrochloride) is the deuterium labeled Eletriptan hydrochloride . Eletriptan (UK-116044) hydrochloride is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan hydrochloride has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan hydrochloride can be used for researching migraine .

HY-B0121BS1

Sumatriptan-d6
Sumatriptan-d₆ is the deuterium labeled Sumatriptan. Sumatriptan is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-12366S

Ubrogepant-d5
Ubrogepant-d₅ (MK-1602-d₅) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .

HY-B0121BS

Sumatriptan-d6 succinate 1 Publications Verification
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with K_is of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .

HY-B1716S1

L-5-Hydroxytryptophan-d3-1

L-5-Hydroxytryptophan-d₃-1 is the deuterium labeled L-5-Hydroxytryptophan . L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-B0121BS3

Sumatriptan-d6 formate
Sumatriptan-d₆ (formate) (GR 43175 free base-d₆ (formate)) is deuterium labeled Sumatriptan. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-B0197S

Naratriptan-d3

Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan (HY-B0197). Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-B0383AS

Almotriptan hydrochloride-d6

Almotriptan-d₆ (PNU180638-d₆) hydrochloride is the deuterium labeled Almotriptan hydrochloride. Almotriptan hydrochloride is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan hydrochloride shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan hydrochloride induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan hydrochloride can be used in research related to migraine.

HY-B1658BS

Frovatriptan-d3 succinate

Frovatriptan-d₃ (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research .

HY-B0383AS2

Almotriptan-d3 benzoate

Almotriptan-d₃ benzoate (PNU180638 free base-d₃) is deuterated labeled Almotriptan benzoate. Almotriptan benzoate is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan benzoate shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan benzoate induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan benzoate can be used in research related to migraine.

HY-143797S

Almotriptan-d6 maleate

Almotriptan-d₆ (PNU180638-d₆) maleate is the deuterium labeled Almotriptan maleate. Almotriptan malate is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan malate shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan malate induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan malate can be used in research related to migraine.

HY-B1716SA

L-5-Hydroxytryptophan-d3 hydrate

L-5-Hydroxytryptophan-d₃ (L-5-HTP-d₃) hydrate is the deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan-d₃ is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

migraines

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products